Article · 26 Oct 2026
EditorialPublished 29 Oct 2021
Heightening Energetic Stress Nonâ??Small Cell Lung Cancers
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Inactivation of the LKB1 cancer silencer is a regular occasion in non–little cell lung carcinoma (NSCLC) prompting the initiation of mTOR complex 1 (mTORC1) and affectability to the metabolic pressure inducer phenformin. In this review, we investigated the combinatorial utilization of phenformin with the mTOR synergist kinase inhibitor MLN0128 as a treatment procedure for NSCLC bearing comutations in the LKB1 and KRAS qualities. NSCLC is a hereditarily and neurotically heterogeneous sickness, leading to lung cancers of fluctuating histologies that incorporate adenocarcinomas and squamous cell carcinomas (SCC). We exhibit that phenformin in mix with MLN0128 actuated a huge restorative reaction in KRAS/LKB1–freak human cell lines and hereditarily designed mouse models of NSCLC that foster the two adenocarcinomas and SCCs.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Cancer Clinical Trials.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cancer Clinical Trials
- SubjectOncology & Cancer
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ruty Toren”
